MHRA approves donidalorsen (Dawnzera) for the treatment of hereditary angioedema
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 7 May 2026, approved donidalorsen (Dawnzera) for use in patients 12 years and…
Browsing Category